For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have ...

Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is ...

Cryotherapy is emerging as a promising strategy to prevent chemotherapy-induced peripheral neuropathy, but adoption in clinical practice remains limited.

A stem cell therapy trial aimed at reducing neuroinflammation in patients with presymptomatic Alzheimer's disease is underway at UTHealth Houston.

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Thursday. The firm issued a buy rating on the biotechnology company’s ...

Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...

The company will publish its Full-Year 2024 financial results on March 26, 2025. On the reporting date, BioVersys will issue a press release at 7:00 AM CET.

RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities ...